00842nas a2200313   4500000000100000000000100001008004100002100001500043700001400058700001400072700001600086700001300102700001300115700001300128700001300141700001400154700001300168700001400181700002200195700001000217700001900227700001700246700001600263700001400279245018400293300001200477490000700489022003200496       2021                            d1 aV. Hoffman1 aJ. Hallas1 aM. Linder1 aA. Margulis1 aB. Suehs1 aA. Arana1 aK. Phiri1 aC. Enger1 aL. Horter1 aI. Odsbu1 aM. Olesen1 aS. Perez-Gutthann1 aY. Xu1 aN. Kristiansen1 aK. Appenteng1 aS. de Vogel1 aJ. Seeger00aCardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study  a899-9150 v44  a0114-5916 (Print) 0114-5916